Albireo Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Albireo Pharma (ALBO) Reports Q3 Loss of $1.17, Revenues Miss
November 13, 2018 7:03 AM ESTAlbireo Pharma (NASDAQ: ALBO) reported Q3 EPS of ($1.17), versus $0.00 reported last year. Revenue for the quarter came in at $237 thousand versus the consensus estimate of $1.27 million.
With our Phase 3 clinical trial of A4250 for progressive familial intrahepatic cholestasis (PFIC) progressing... More
